Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It does not constitute medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional based on individual patient circumstances, current clinical guidelines, and sound medical judgment. Specific patient care should be individualized. Always consult the latest guidelines and primary literature.

---

Stroke

Overview

• Definition: Stroke, also known as a cerebrovascular accident (CVA), is a medical emergency characterized by an acute neurological deficit resulting from impaired blood flow to a specific area of the brain, spinal cord, or retina. This interruption in blood supply can be due to ischemia (lack of blood flow) or hemorrhage (bleeding). It leads to brain cell death within minutes to hours if not promptly reversed.
• Epidemiology:
  • Globally, stroke is the second leading cause of death and a major cause of adult disability.
  • Incidence increases with age, but strokes can occur at any age.
  • Slightly more common in men than women, though women tend to have worse outcomes and higher mortality.
  • Higher prevalence and worse outcomes in certain racial/ethnic groups (e.g., African Americans).
  • Approximately 87% of all strokes are ischemic, while 13% are hemorrhagic.
• Classification:
  • Ischemic Stroke (87%): Caused by an obstruction to blood flow to the brain, most commonly due to a thrombus or embolus.
    • Thrombotic Stroke: Clot forms in a brain artery.
      • Large-vessel thrombosis: Often associated with atherosclerosis.
      • Small-vessel thrombosis (Lacunar stroke): Affects small, deep brain arteries, often associated with hypertension and diabetes.
    • Embolic Stroke: Clot travels from another part of the body (e.g., heart in atrial fibrillation, carotid artery) to the brain.
    • Cryptogenic Stroke: Ischemic stroke where no definite cause is identified despite thorough investigation (also known as Embolic Stroke of Undetermined Source - ESUS).
    • Other causes: Vasculitis, arterial dissection, hypercoagulable states, illicit drug use.
  • Hemorrhagic Stroke (13%): Caused by a rupture of a blood vessel leading to bleeding within or around the brain.
    • Intracerebral Hemorrhage (ICH): Bleeding directly into the brain tissue. Most commonly caused by uncontrolled hypertension, amyloid angiopathy, vascular malformations, or anticoagulant use.
    • Subarachnoid Hemorrhage (SAH): Bleeding into the subarachnoid space (the space between the brain and the membranes that cover it). Most commonly caused by a ruptured aneurysm, but also by arteriovenous malformations (AVMs) or trauma.
  • Transient Ischemic Attack (TIA): A transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. Symptoms typically resolve within minutes to an hour. Often considered a "mini-stroke" and is a strong warning sign for future full stroke.

Pathophysiology

• Mechanism:
  • Ischemic Stroke: An acute reduction or cessation of blood flow to a region of the brain. This leads to a cascade of events:
    1. Energy Failure: Oxygen and glucose deprivation leads to ATP depletion.
    2. Ion Pump Failure: Na+/K+-ATPase failure leads to cellular depolarization, causing influx of Na+, Cl-, and water into the cell (cytotoxic edema), and efflux of K+.
    3. Excitotoxicity: Release of excitatory neurotransmitters (e.g., glutamate) overactivates NMDA receptors, leading to excessive intracellular Ca2+ influx. This triggers enzyme activation (proteases, lipases, endonucleases) and free radical production.
    4. Inflammation and Oxidative Stress: Macrophages and microglia activate, releasing inflammatory mediators and reactive oxygen species, further damaging brain tissue.
    5. Apoptosis and Necrosis: Ultimately, these processes lead to irreversible neuronal death (infarction). * Ischemic Penumbra: A region of brain tissue surrounding the core ischemic area. While perfusion is reduced, it is not low enough to cause immediate cell death. This tissue is salvageable if blood flow is restored quickly, making it the primary target of acute reperfusion therapies.
  • Hemorrhagic Stroke: Rupture of a blood vessel results in hematoma formation.
    1. Direct Tissue Damage: Blood extravasating into brain parenchyma or subarachn space directly injures neurons.
    2. Mass Effect: The expanding hematoma compresses surrounding brain tissue, leading to increased intracranial pressure (ICP) and potential herniation.
    3. Secondary Injury: Blood products (e.g., hemoglobin breakdown products) can be toxic to neurons and glia, inducing inflammation, oxidative stress, and excitotoxicity in the surrounding tissue. In SAH, vasospasm of cerebral arteries is a major delayed complication, leading to secondary ischemia.
• Risk Factors:
  • Modifiable:
    • Hypertension (most significant, target BP <130/80 mmHg in most)
    • Atrial Fibrillation (AFib) (5x increased risk, necessitates anticoagulation)
    • Diabetes Mellitus (target A1c <7.0%)
    • Dyslipidemia (LDL-C <100 mg/dL, often <70 mg/dL or even <55 mg/dL post-stroke)
    • Smoking (cessation reduces risk significantly)
    • Obesity (BMI >30 kg/m²)
    • Physical Inactivity
    • Unhealthy Diet
    • Carotid Artery Stenosis
    • Sickle Cell Disease
    • Heart Disease (e.g., CAD, heart failure, PFO)
    • Sleep Apnea
    • Excessive Alcohol Consumption
    • Illicit Drug Use (especially cocaine, amphetamines)
  • Non-Modifiable:
    • Age (risk doubles each decade after 55)
    • Sex (men higher incidence, women higher mortality)
    • Race/Ethnicity (African Americans, Hispanic, some Asian populations)
    • Family History of Stroke
    • Prior Stroke or TIA (highest risk factor for future stroke)
    • Genetic factors (e.g., CADASIL, certain prothrombotic mutations)
• Protective Factors:
  • Healthy lifestyle (regular physical activity, balanced diet low in saturated fats and high in fruits/vegetables)
  • Strict control of modifiable risk factors (BP, blood glucose, cholesterol)
  • Smoking cessation
  • Moderate alcohol consumption (or abstinence)
  • Early detection and treatment of AFib
  • Management of carotid artery disease

Clinical Presentation

Signs and Symptoms

Stroke symptoms are acute in onset and reflect the brain region affected. - Cardinal Features (FAST acronym for public awareness): * Face drooping: One side of the face droops or is numb. * Arm weakness: One arm is weak or numb. * Speech difficulty: Slurred speech, difficulty speaking, or difficulty understanding speech. * Time to call 911: If any of these signs are present, even if they disappear, call for emergency medical help immediately. - Early Signs: * Sudden numbness or weakness of the face, arm, or leg, especially on one side of the body. * Sudden confusion, trouble speaking, or difficulty understanding speech. * Sudden trouble seeing in one or both eyes (e.g., monocular vision loss, homonymous hemianopia). * Sudden trouble walking, dizziness, loss of balance or coordination. * Sudden severe headache with no known cause (often described as "the worst headache of my life" in SAH). - Advanced Signs (can indicate larger stroke, specific locations, or complications): * Hemiplegia or severe hemiparesis. * Global aphasia. * Neglect (inability to perceive stimuli on one side of the body/space). * Visual field cuts. * Ataxia, vertigo, nystagmus (posterior circulation stroke). * Altered level of consciousness, stupor, coma (especially in large strokes, brainstem strokes, or hemorrhagic strokes with significant mass effect). * Pupillary abnormalities, gaze deviation. * Seizures (can occur at onset or as a complication). - Atypical Presentations: * Isolated dizziness, vertigo, or imbalance without other brainstem signs. * Sudden confusion or delirium in elderly patients without classic focal deficits. * Acute onset of psychiatric symptoms (rare). * Only sensory symptoms without motor weakness. * Transient global amnesia-like symptoms (though TGA is distinct from TIA/stroke). * Isolated headache in absence of focal deficits (can occur in SAH). * "Watershed" strokes can present with proximal limb weakness without clear unilateral distribution.

Physical Examination

A thorough neurological examination is crucial, often quantified using scales like the NIH Stroke Scale (NIHSS). - Inspection: * General appearance: Level of consciousness, signs of distress. * Facial symmetry: Observe for facial droop (e.g., flattening of nasolabial fold, mouth deviation) on smiling. * Pupils: Size, symmetry, reactivity to light (anisocoria, unreactive pupils can indicate severe brain injury or herniation). * Eye movements: Gaze deviation (conjugate gaze preference towards the side of the lesion in hemispheric strokes, or away in pontine lesions), nystagmus, diplopia, extraocular movements. * Body posture and movement: Spontaneous movements, posturing (decorticate/decerebrate), signs of hemiparesis or hemiplegia (e.g., arm internally rotated, adducted, elbow flexed; leg extended and externally rotated). * Speech: Dysarthria (slurred speech), aphasia (difficulty producing or comprehending language). - Palpation: * Carotid arteries: Auscultate for bruits (suggests stenosis), but avoid vigorous palpation, especially bilateral, due to risk of dislodging emboli or causing bradycardia. * Peripheral pulses: Assess for signs of peripheral artery disease, which can be a marker for generalized atherosclerosis. * Skin: Check for signs of trauma (especially in SAH or falls related to stroke onset). - Special Tests: * Vital Signs: Blood pressure (BP), heart rate, respiratory rate, temperature, oxygen saturation. BP is critical: very high BP can indicate hemorrhage or compensatory mechanism for ischemia; very low BP can exacerbate ischemia. * Neurological Examination (Detailed): * Cranial Nerves: Assess all 12, focusing on facial symmetry (VII), visual fields (II), pupillary reflexes (II, III), extraocular movements (III, IV, VI), swallowing (IX, X), tongue deviation (XII). * Motor Strength: Test strength in all four extremities (0-5 scale). Look for pronator drift. * Sensory: Light touch, pinprick, temperature, proprioception. * Coordination: Finger-to-nose, heel-to-shin, gait. * Reflexes: Deep tendon reflexes (DTRs) may be hyperreflexic or hyporeflexic; presence of pathological reflexes (Babinski sign). * NIH Stroke Scale (NIHSS): A standardized, validated, 15-item neurological examination tool used to objectively quantify the severity of stroke deficits. Scores range from 0 (no stroke) to 42 (severe stroke). Essential for guiding acute treatment decisions and monitoring changes. * Rapid Arterial Occlusion Scale (RACE) or LAMS (Los Angeles Motor Scale): Pre-hospital scales to identify patients with suspected large vessel occlusion (LVO) who may benefit from endovascular thrombectomy.

Diagnostic Approach

History Taking

Time is Brain! Ascertaining the "last known normal" (LKN) time is the single most critical piece of information, as it dictates eligibility for acute reperfusion therapies. - Key Questions: * Onset: When were the symptoms first noticed? Or, more precisely, when was the patient last known to be completely normal? (Crucial for time window calculations). * Nature of symptoms: Detailed description of initial symptoms and their evolution. * Associated symptoms: Headache, nausea, vomiting, dizziness, altered consciousness, seizure. * Past Medical History: Hypertension, diabetes, hyperlipidemia, atrial fibrillation, prior stroke/TIA, heart disease, smoking, alcohol/drug use. * Current Medications: Especially anticoagulants (warfarin, DOACs), antiplatelets. * Recent events: Trauma, falls, neck manipulation, fever, infection. * Family History: Stroke, aneurysm, genetic conditions. * Travel history (e.g., for vasculitis consideration). - Red Flags: * Acute onset of focal neurological deficit. * "Worst headache of my life" (classic for SAH). * Sudden, severe, unprovoked headache with stiff neck and altered consciousness. * GCS <15, or rapidly declining level of consciousness. * Signs of brainstem dysfunction (e.g., "crossed" deficits, nystagmus, pupillary abnormalities). * Evidence of recent head trauma or falls. * Known history of anticoagulation or bleeding disorders.

Laboratory Tests

• First-Line (immediately upon arrival):
  • Complete Blood Count (CBC): To assess for anemia, thrombocytosis, leukocytosis (infection or inflammatory response).
  • Coagulation Panel (PT/INR, aPTT): Essential if considering thrombolytics (IV tPA) or if patient is on anticoagulants. Helps rule out coagulopathy.
  • Blood Glucose: Hypoglycemia can mimic stroke symptoms ("stroke mimic"); hyperglycemia can worsen ischemic brain injury. Administer D50W for hypoglycemia (<60 mg/dL).
  • Electrolytes, Renal Function (BUN/Cr): For general status, medication dosing, and contrast imaging.
  • Cardiac Enzymes (Troponin): To rule out myocardial ischemia/infarction, which can be a source of emboli or co-exist.
  • ECG: To detect atrial fibrillation, other arrhythmias, or signs of acute myocardial ischemia. AFib is a major cause of cardioembolic stroke.
  • Oxygen Saturation: Hypoxia can worsen brain injury.
  • Alcohol/Drug Screen (Tox screen): If suspected, to rule out stroke mimics or contributing factors.
  • Pregnancy test: For women of childbearing potential, especially before imaging or medications.
• Confirmatory (once acute management is underway or based on initial findings):
  • Lipid Panel: For risk factor assessment, typically performed after the acute phase.
  • HbA1c: For long-term glucose control assessment.
  • Inflammatory markers (ESR, CRP): If vasculitis is suspected.
  • Thyroid function tests: Hyperthyroidism can cause AFib.
  • Autoimmune panel: If autoimmune vasculitis or hypercoagulable state is suspected.
  • Homocysteine, Factor V Leiden, Protein C/S deficiency, Antithrombin III deficiency, Antiphospholipid Antibodies: For hypercoagulable workup, particularly in younger patients or those with cryptogenic stroke.
• Monitoring:
  • Serial neurological exams (e.g., NIHSS)
  • Blood pressure monitoring
  • Blood glucose monitoring (especially in diabetics or those on steroids)
  • Electrolytes (e.g., for SIADH in SAH)
  • Coagulation parameters if patient is on anticoagulants or has a bleeding complication.

Imaging

• Recommended (Urgent, within 20-25 minutes of arrival):
  • Non-contrast Head CT (NCCT): This is the critical initial imaging study.
    • Purpose: To rapidly differentiate between ischemic stroke and hemorrhagic stroke.
    • Findings:
      • Ischemic stroke: NCCT is often normal in the first 3-6 hours. Early subtle signs (e.g., hyperdense MCA sign, insular ribbon sign, sulcal effacement, loss of gray-white differentiation) suggest ischemia.
      • Hemorrhagic stroke: Acute blood appears hyperdense (bright white) immediately on CT.
      • Exclusion: Rules out other conditions mimicking stroke (e.g., tumor, abscess).
  • CT Angiography (CTA) of the Head and Neck:
    • Purpose: If ischemic stroke is suspected, CTA identifies large vessel occlusions (LVOs) in the intracranial or extracranial carotid and vertebral arteries. It is crucial for selecting patients for endovascular thrombectomy.
    • Findings: Visualizes arterial anatomy and occlusion sites.
  • CT Perfusion (CTP):
    • Purpose: Measures cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT). Identifies the ischemic core (irreversibly damaged tissue) and the ischemic penumbra (at-risk but salvageable tissue).
    • Findings: Helps determine if there is salvageable brain tissue, especially in extended time windows or "wake-up" strokes.
• Advanced (When needed, often after initial stabilization or for specific diagnoses):
  • MRI Brain with Diffusion-Weighted Imaging (DWI):
    • Purpose: More sensitive than CT for detecting acute ischemic stroke, often within minutes of onset. Also useful for differentiating acute from chronic lesions.
    • Findings: DWI shows cytotoxic edema (restricted diffusion) in the ischemic core early. Fluid-attenuated inversion recovery (FLAIR) sequences can help estimate stroke age (DWI-FLAIR mismatch suggests acute stroke in "wake-up" or unknown onset stroke).
    • MR Angiography (MRA): Provides similar information to CTA regarding vessel patency but without ionizing radiation or iodine contrast (though gadolinium contrast may be used).
  • Transcranial Doppler (TCD) or Carotid Duplex Ultrasound:
    • Purpose: Non-invasive assessment of carotid and vertebral artery stenosis and intracranial blood flow velocities. Can be used to monitor for vasospasm in SAH.
  • Echocardiography (Transthoracic or Transesophageal):
    • Purpose: To identify cardiac sources of emboli (e.g., mural thrombus, PFO, endocarditis, valvular heart disease). Transesophageal echo (TEE) is more sensitive for atrial thrombi and PFO.
  • Digital Subtraction Angiography (DSA):
    • Purpose: "Gold standard" for visualizing cerebral vasculature. Used when non-invasive imaging is inconclusive or for intervention (e.g., coiling of an aneurysm, AVM embolization, stenting).

Management

Acute Management (Goal: Restore blood flow rapidly for ischemic stroke; control bleeding and ICP for hemorrhagic stroke)

"Time is Brain" - Every minute counts. - Immediate (Within 10-20 minutes of arrival): * Activate Stroke Team: Promptly involve neurology, neurosurgery (for hemorrhage), interventional radiology. * ABCs (Airway, Breathing, Circulation): * Assess and secure airway if necessary (GCS <8, impending respiratory failure). * Administer oxygen if SpO2 <94%. * Establish IV access (2 large bore IVs). * Cardiac monitoring. * Rapid Neurological Assessment: NIHSS score, GCS. * Point-of-Care Glucose: Correct hypoglycemia immediately (e.g., D50W 25g IV). * Stat NCCT Head: To differentiate ischemic from hemorrhagic stroke. * Labs: CBC, Coags (PT/INR, aPTT), Renal, Electrolytes, Troponin. * ECG. - Stabilization (Initial hours): * Blood Pressure Management: * Ischemic Stroke (eligible for IV tPA): Maintain BP ≤185/110 mmHg before tPA. If tPA given, maintain BP ≤180/105 mmHg for at least 24 hours post-tPA. Common agents: Labetalol 10-20 mg IV push over 1-2 min (may repeat once), Nicardipine 5 mg/h IV infusion (titrate up by 2.5 mg/h every 5-15 min to max 15 mg/h), Clevidipine 1-2 mg/h IV. * Ischemic Stroke (NOT eligible for IV tPA): Permit permissive hypertension up to 220/120 mmHg in the first 24-48 hours, unless there is evidence of acute organ damage (e.g., aortic dissection, acute MI, acute renal failure, heart failure). Aggressive BP lowering can decrease cerebral perfusion and worsen ischemia. * Hemorrhagic Stroke (ICH): Target systolic BP 140-160 mmHg. Rapid lowering to <140 mmHg is controversial but generally considered for SBP >200 mmHg. Agents: Nicardipine, Labetalol, Hydralazine, Esmolol. * SAH: Maintain SBP 120-160 mmHg; avoid hypotension. * Temperature Control: Treat fever (>38°C) aggressively with antipyretics (e.g., acetaminophen) as hyperthermia worsens brain injury. * Glycemic Control: Maintain blood glucose 140-180 mg/dL. Treat hypoglycemia (<60 mg/dL) and significant hyperglycemia (>180-200 mg/dL). * Dysphagia Screen: All stroke patients should undergo a formal dysphagia screen before oral intake (food, liquids, medication) to prevent aspiration pneumonia. - Emergency (Reperfusion for Ischemic Stroke / Bleeding Control for Hemorrhagic Stroke): * Acute Ischemic Stroke Reperfusion Therapies: * Intravenous Thrombolysis (IV tPA / Alteplase): * Mechanism: A recombinant tissue plasminogen activator that catalyzes the conversion of plasminogen to plasmin, leading to fibrinolysis and clot dissolution. * Criteria: Adult patients with disabling neurological deficit, time of LKN <4.5 hours from symptom onset. * Dose: 0.9 mg/kg total dose (max 90 mg). 10% given as initial IV bolus over 1 minute, remaining 90% infused over 60 minutes. * Exclusion Criteria (Key): Evidence of hemorrhage on NCCT, LKN >4.5 hours, recent surgery/trauma, active internal bleeding, history of ICH, bleeding diathesis (e.g., INR >1.7, aPTT >40s, PLT <100,000), severe uncontrolled HTN (>185/110 mmHg), rapidly improving symptoms. (Numerous detailed criteria exist; refer to AHA/ASA guidelines). * Endovascular Thrombectomy (EVT): * Mechanism: Mechanical removal of a large cerebral artery clot using a catheter-based device (stent retriever, aspiration device). * Criteria: Patients with LVO (internal carotid artery or M1/M2 segments of MCA, basilar artery) who meet specific imaging and clinical criteria. LKN typically <6 hours, but can be extended up to 24 hours in select patients based on advanced imaging (CTP/MRI DWI-FLAIR) showing a favorable penumbra. * Benefit: Highly effective in reducing disability, particularly for anterior circulation LVO. Can be used in addition to IV tPA if eligible. * Acute Hemorrhagic Stroke Management: * Intracerebral Hemorrhage (ICH): * Rapid reversal of anticoagulation: If on warfarin (Vitamin K + PCC/factor VIIa), DOACs (idarucizumab for dabigatran, andexanet alfa for rivaroxaban/apixaban; PCC for others). * Blood pressure control: Target SBP 140-160 mmHg (AHA/ASA IIa, SBP 150-220 mmHg can be safely and effectively lowered to SBP 140 mmHg). * ICP management: Head of bed elevation, hyperventilation, mannitol or hypertonic saline if signs of herniation. * Neurosurgical consultation: For hematoma evacuation (e.g., cerebellar hemorrhage >3 cm with neurological deterioration, large lobar ICH with clinical decline, intraventricular hemorrhage with hydrocephalus). * Subarachnoid Hemorrhage (SAH): * Aneurysm securing: Endovascular coiling or surgical clipping to prevent rebleeding. Performed as soon as feasible. * Nimodipine: Oral calcium channel blocker (60 mg q4h for 21 days) to prevent delayed cerebral ischemia due to vasospasm. Does not prevent vasospasm but improves outcomes. * Maintain euvolemia and normotension: Avoid hypotension. * Manage hydrocephalus: External ventricular drain (EVD) placement if needed.

Chronic Management (Secondary Prevention & Rehabilitation)

• Pharmacological:
  • Antiplatelet Therapy (Ischemic Stroke/TIA):
    • Rationale: Prevents new clot formation by inhibiting platelet aggregation.
    • First-line: Aspirin (ASA) 81-325 mg daily (e.g., 81 mg daily).
    • Alternative/Add-on: Clopidogrel 75 mg daily (for ASA allergy or intolerance, or for certain high-risk TIA/minor stroke - e.g., dual antiplatelet for 21-90 days).
    • Dual Antiplatelet Therapy (DAPT): ASA + Clopidogrel for 21-90 days (starting within 24 hours) for high-risk TIA (ABCD2 score ≥4) or minor ischemic stroke (NIHSS ≤3) is recommended to reduce early recurrent stroke risk. Beyond 90 days, typically reverts to monotherapy.
    • Dipyridamole extended-release + Aspirin (Aggrenox): Can be considered as an alternative to clopidogrel monotherapy.
  • Anticoagulation Therapy (Cardioembolic Stroke):
    • Rationale: Prevents clot formation in the heart (e.g., in AFib) from embolizing to the brain.
    • Agents:
      • Direct Oral Anticoagulants (DOACs): Apixaban, Dabigatran, Edoxaban, Rivaroxaban are preferred over warfarin for non-valvular AFib due to similar or superior efficacy and lower ICH risk.
      • Warfarin: Vitamin K antagonist, requires regular INR monitoring. Used for mechanical heart valves or specific conditions where DOACs are not indicated.
    • Timing: Generally initiated 4-14 days post-stroke depending on stroke size, risk of hemorrhagic transformation, and renal function. Small strokes may start sooner (e.g., 3-5 days), large strokes later (e.g., 10-14 days or even longer).
  • Statins (Ischemic Stroke/TIA):
    • Rationale: Reduces LDL-C and provides pleiotropic effects (anti-inflammatory, endothelial stabilization) that reduce atherosclerotic plaque progression and recurrent stroke risk.
    • Recommendation: High-intensity statin therapy (e.g., Atorvastatin 40-80 mg daily, Rosuvastatin 20-40 mg daily) is recommended for all patients with atherosclerotic ischemic stroke or TIA, regardless of baseline LDL-C, with a target LDL-C <70 mg/dL.
  • Antihypertensive Agents:
    • Rationale: Strict blood pressure control is the most effective strategy for preventing recurrent stroke.
    • Recommendation: For patients with ischemic stroke or TIA and hypertension, target BP <130/80 mmHg. ACE inhibitors, ARBs, thiazide diuretics are commonly used.
  • Anticonvulsants: If post-stroke seizures occur. Prophylactic anticonvulsants are generally NOT recommended.
• Non-pharmacological:
  • Lifestyle Modification:
    • Diet: DASH diet, Mediterranean diet (low sodium, saturated fat; high fruits, vegetables, whole grains).
    • Exercise: Regular physical activity (e.g., 30 minutes of moderate intensity most days of the week).
    • Weight Management: Achieve and maintain a healthy BMI (18.5-24.9 kg/m²).
    • Smoking Cessation: Crucial. Provide resources and support.
    • Alcohol Moderation: Limit alcohol intake.
  • Rehabilitation: Essential for maximizing functional recovery and quality of life.
    • Physical Therapy (PT): Restores motor function, strength, balance, and gait.
    • Occupational Therapy (OT): Helps with activities of daily living (ADLs) and instrumental ADLs (IADLs), adaptive equipment.
    • Speech-Language Pathology (SLP): Addresses aphasia, dysarthria, dysphagia.
    • Cognitive Rehabilitation: For memory, attention, executive function deficits.
    • Psychological Support: For depression, anxiety, adjustment to disability.
  • Carotid Endarterectomy (CEA) or Stenting (CAS): For symptomatic carotid artery stenosis (>50% to >70%). Decisions depend on patient factors, comorbidities, and institutional expertise.
  • Patent Foramen Ovale (PFO) Closure: For cryptogenic stroke patients, especially younger adults, after thorough evaluation to rule out other causes. Recent trials (CLOSE, RESPECT, REDUCE) support PFO closure over antiplatelet therapy alone in selected patients.
• Monitoring:
  • Regular follow-up with neurology, primary care, and rehabilitation specialists.
  • Regular blood pressure checks.
  • Lipid panel monitoring (especially for statin efficacy).
  • Blood glucose monitoring (HbA1c).
  • INR monitoring for warfarin, or adherence for DOACs.
  • Assessment for depression, anxiety.
  • Screening for recurrent stroke symptoms.

Treatment Algorithms

Acute Ischemic Stroke Pathway (Simplified): 1. Suspected Stroke (Pre-hospital/ED) * Goal: Rapid Recognition (FAST), Emergency Activation (EMS/Stroke Team), Rapid Transport to Stroke Center. * Key Action: Determine Last Known Normal (LKN) time. 2. Emergency Department Arrival (Within 10-20 minutes) * Assess: ABCs, Vitals, Glucose, NIHSS. * Stat NCCT Head: Rule out hemorrhage. * Labs: CBC, Coags, Troponin, ECG. 3. NCCT Results (<20-25 minutes) * If Hemorrhage: Proceed to Hemorrhagic Stroke Protocol (reverse anticoagulation, BP control, neurosurgical consult). * If No Hemorrhage (Ischemic Stroke Suspected): * Further Imaging: CTA Head/Neck, CTP (depending on time window/center protocol). 4. Decision Point: IV tPA Eligibility * LKN <4.5 hours and No Contraindications: Administer IV tPA (0.9 mg/kg, 10% bolus, 90% infusion). * If LKN >4.5 hours or Contraindications: Do NOT administer IV tPA. 5. Decision Point: Large Vessel Occlusion (LVO) & EVT Eligibility * Evidence of LVO on CTA and meets EVT criteria (e.g., LKN <6 hours or up to 24 hours with favorable CTP/MRI): Proceed to Endovascular Thrombectomy (EVT). * If also tPA eligible: Administer tPA first, then transfer for EVT. * No LVO or Not EVT Eligible: Medical management only. 6. Post-Acute Care: * Monitoring: Neuro checks, BP, glucose, complications. * Secondary Prevention: Antiplatelets/Anticoagulation, Statins, BP control, lifestyle. * Rehabilitation: PT, OT, SLP.

First-Line (Acute): * Ischemic Stroke: IV tPA (if eligible, LKN <4.5h), Endovascular Thrombectomy (if eligible, LVO, LKN <24h with appropriate imaging). * Hemorrhagic Stroke: Immediate BP control, reversal of anticoagulation, neurosurgical consultation for aneurysm clipping/coiling (SAH) or hematoma evacuation (ICH).

Second-Line (Acute): * Tenecteplase (TNK) may be considered as an alternative to alteplase for IV thrombolysis, particularly if rapid bolus administration is advantageous, and has shown non-inferiority in some trials. Its use is increasing but not yet universal.

Refractory Cases (Acute): * Malignant MCA Infarction: Decompressive hemicraniectomy for large anterior circulation ischemic strokes causing severe cerebral edema and neurological deterioration, particularly in patients <60 years old. Improves survival and functional outcome. * Refractory ICH/SAH: Continued aggressive BP and ICP management, neurosurgical interventions as indicated.

Complications

• Common:
  • Aspiration Pneumonia: Due to dysphagia, common in acute stroke.
  • Urinary Tract Infections (UTI): Often related to catheterization or neurogenic bladder.
  • Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE): Due to immobility and hypercoagulable state. Prophylactic anticoagulation (e.g., LMWH) and mechanical prophylaxis (e.g., intermittent pneumatic compression devices) are crucial.
  • Depression and Anxiety: Very common post-stroke, often underestimated. Requires screening and treatment.
  • Seizures: Can occur acutely or later.
  • Fatigue: Debilitating for many survivors.
• Serious:
  • Cerebral Edema (Malignant Brain Edema): Especially in large ischemic strokes or ICH. Can lead to increased ICP, brain herniation, and death.
  • Hemorrhagic Transformation: Ischemic stroke can convert to hemorrhagic stroke, especially after thrombolysis.
  • Rebleeding (SAH): A major risk, especially before an aneurysm is secured.
  • Vasospasm (SAH): Delayed cerebral ischemia due to arterial narrowing, typically 3-14 days post-SAH.
  • Hydrocephalus: Accumulation of CSF in ventricles, can occur in ICH or SAH.
  • Herniation Syndromes: Uncal, central, tonsillar, cingulate. Life-threatening.
  • Cardiac Complications: Arrhythmias, myocardial infarction, neurogenic stunned myocardium.
  • Sepsis: From pneumonia or UTI.
• Long-term:
  • Spasticity: Increased muscle tone, affecting movement and causing pain.
  • Contractures: Permanent shortening of muscles/tendons due to spasticity or immobility.
  • Chronic Pain: Central post-stroke pain syndrome, neuropathic pain.
  • Cognitive Impairment / Vascular Dementia: Memory, attention, executive function deficits.
  • Aphasia / Dysarthria: Persistent communication difficulties.
  • Swallowing Difficulties (Dysphagia): Leading to malnutrition and aspiration risk.
  • Gait and Balance Impairment: Increased fall risk.
  • Emotional Lability / Pseudobulbar Affect: Uncontrollable laughing or crying.
  • Sexual Dysfunction.
  • Social Isolation and Economic Burden.

Prognosis

• Factors:
  • Initial Stroke Severity: Quantified by NIHSS (higher score = worse prognosis).
  • Age: Older age is associated with worse outcomes and higher mortality.
  • Stroke Type and Location: Hemorrhagic strokes generally have higher acute mortality. Brainstem strokes often have severe deficits. Large hemispheric ischemic strokes carry high morbidity and mortality.
  • Time to Reperfusion: Shorter time to thrombolysis/thrombectomy leads to better outcomes in ischemic stroke.
  • Comorbidities: Pre-existing conditions (e.g., diabetes, heart failure, renal disease) worsen prognosis.
  • Complications: Development of pneumonia, edema, or hemorrhagic transformation worsens outcomes.
  • Access to Rehabilitation: Intensive, early rehabilitation improves functional recovery.
  • Social Support: Strong social support networks correlate with better long-term recovery.
• Survival:
  • Ischemic Stroke: Overall 30-day mortality around 10-15%; 1-year mortality 15-20%.
  • Intracerebral Hemorrhage: Higher acute mortality, 30-day mortality around 35-50%.
  • Subarachnoid Hemorrhage: High initial mortality (10-15% die before reaching hospital), 30-day mortality up to 40-50%.
  • Approximately 10% of stroke survivors recover almost completely, 25% recover with minor impairments, 40% experience moderate to severe impairments requiring special care, and 10% require institutionalization.
• Quality of Life:
  • Stroke significantly impacts quality of life due to physical, cognitive, and emotional deficits.
  • Functional independence (measured by Modified Rankin Scale, MRS, where 0=no symptoms, 6=death) is a key outcome measure. An MRS score of 0-2 is considered a good outcome.
  • Depression, anxiety, and fatigue are major contributors to reduced quality of life.

Prevention

• Primary Prevention (Before a stroke occurs):
  • Lifestyle Modification: Healthy diet (DASH, Mediterranean), regular physical activity, maintaining healthy weight, smoking cessation, moderate alcohol intake.
  • Aggressive Management of Risk Factors:
    • Hypertension: Goal <130/80 mmHg. Lifestyle modifications and pharmacological therapy (thiazide diuretics, ACE inhibitors, ARBs, CCBs).
    • Diabetes Mellitus: Optimal glycemic control (HbA1c <7%).
    • Dyslipidemia: Statin therapy for high-risk individuals; target LDL-C based on risk profile.
    • Atrial Fibrillation: Anticoagulation (DOACs or warfarin) for high-risk patients (CHA2DS2-VASc score).
    • Carotid Artery Stenosis: Antiplatelet therapy. Consider CEA/CAS for asymptomatic severe stenosis in selected patients.
    • Sleep Apnea: Diagnosis and treatment.
    • Aspirin: Not routinely recommended for primary prevention in low-risk individuals due to bleeding risk. May be considered for very specific high-risk individuals (e.g., high ASCVD risk without increased bleeding risk), but this is debated.
• Secondary Prevention (After a TIA or stroke, to prevent recurrence):
  • Antiplatelet Therapy: For ischemic stroke/TIA (not cardioembolic). Usually ASA or clopidogrel monotherapy, or DAPT for short duration in high-risk minor stroke/TIA.
  • Anticoagulation: For cardioembolic stroke (e.g., AFib, mechanical heart valve). DOACs preferred for non-valvular AFib.
  • High-Intensity Statin Therapy: For atherosclerotic ischemic stroke/TIA, target LDL-C <70 mg/dL (or even lower, <55 mg/dL, in very high-risk).
  • Blood Pressure Control: Target <130/80 mmHg, using antihypertensive agents.
  • Diabetes Control: Optimize glycemic control.
  • Smoking Cessation: Absolute necessity.
  • Carotid Revascularization: CEA or CAS for symptomatic carotid artery stenosis (>50% to >70%).
  • PFO Closure: In selected patients with cryptogenic stroke.
• Tertiary Prevention (Preventing complications and maximizing recovery):
  • Comprehensive Rehabilitation: Physical, occupational, speech therapy, psychological support.
  • Management of Post-Stroke Complications: Prophylaxis for DVT/PE, treatment of dysphagia, spasticity, pain, depression.
  • Patient and Caregiver Education: On risk factor management, medication adherence, recognizing recurrent stroke symptoms.

Special Populations

• Pediatric Stroke:
  • Epidemiology: Less common but significant cause of morbidity. Often higher proportion of hemorrhagic strokes.
  • Etiology: Different from adults. Common causes include sickle cell disease, congenital heart disease, arteriopathies (e.g., moyamoya), arterial dissection, genetic disorders, and prothrombotic conditions.
  • Presentation: Often atypical (seizures, altered consciousness, focal deficits might be subtle or non-specific). Headache, lethargy, developmental regression.
  • Management: Similar acute principles (ABCs, imaging, glucose). Thrombolysis (tPA) and thrombectomy are considered in carefully selected cases with strict criteria and expertise, but less routinely applied than in adults. Secondary prevention tailored to etiology.
• Geriatric Stroke:
  • Epidemiology: Incidence significantly increases with age. Often more severe strokes, higher mortality, and worse functional outcomes.
  • Comorbidities: More prevalent (AFib, hypertension, diabetes, CAD), increasing stroke risk and complexity of management. Polypharmacy is common.
  • Presentation: May be atypical, subtle, or confused with other age-related conditions. Baseline cognitive impairment can mask deficits.
  • Management: Same acute treatment principles. Higher risk of complications from reperfusion therapies (e.g., bleeding with tPA). Rehabilitation needs are often greater, but older age alone is not a contraindication. Careful consideration of comorbidities and patient goals.
• Pregnancy and Puerperium Stroke:
  • Epidemiology: Stroke risk is increased during pregnancy and especially in the puerperium (postpartum period).
  • Etiology: Eclampsia/preeclampsia, cerebral venous thrombosis (CVT), peripartum cardiomyopathy, arterial dissection, thrombophilias, postpartum angiopathy.
  • Diagnosis: Imaging (MRI preferred over CT to avoid radiation, or lead shielding for CT). D-dimer can be elevated in normal pregnancy.
  • Management: Complex due to fetal considerations.
    • Ischemic Stroke: IV tPA is generally considered for life-threatening maternal stroke, balancing risks. EVT can be performed. Heparin often preferred over warfarin for anticoagulation during pregnancy.
    • Hemorrhagic Stroke: BP management, careful consideration of neurosurgery.
    • CVT: Anticoagulation is cornerstone.
• Comorbidities:
  • Diabetes Mellitus: Increases stroke risk and worsens outcomes. Requires tight glycemic control (HbA1c <7%).
  • Atrial Fibrillation: Major embolic source. Requires long-term anticoagulation (DOACs preferred).
  • Renal Impairment: Affects drug dosing (e.g., tPA, DOACs). Increases risk of contrast-induced nephropathy.
  • Cardiac Disease (Heart Failure, CAD): Increases stroke risk. Requires careful management, avoiding hypotension.

Clinical Pearls

• Diagnostic:
  • Always obtain a CT head without contrast first: To rule out hemorrhage before considering thrombolysis, even if the patient appears ischemic.
  • "Last Known Normal" is paramount: If unknown (e.g., "wake-up stroke"), advanced imaging (CTP or MRI DWI-FLAIR) may help determine candidacy for extended window therapies.
  • Don't forget stroke mimics: Hypoglycemia, seizures (Todd's paralysis), migraine with aura, conversion disorder, Bell's palsy, drug intoxication, encephalitis, brain tumors. Rule these out.
  • NIHSS is a dynamic tool: Use it for initial assessment, guiding treatment, and monitoring changes.
  • Consider Posterior Circulation Stroke: Dizziness, vertigo, ataxia, nystagmus, diplopia, crossed neurological deficits are hallmarks. Can be easily missed.
• Treatment:
  • Adherence to Guidelines: Follow AHA/ASA guidelines meticulously for tPA and EVT, as strict criteria are essential for patient safety and efficacy.
  • BP Management is Key: Permissive hypertension in acute ischemic stroke (non-tPA/EVT) vs. strict control in tPA/EVT patients and hemorrhagic stroke.
  • Dysphagia Screen: Perform before any oral intake to prevent aspiration.
  • Early Mobilization and DVT Prophylaxis: Crucial to prevent complications.
  • Multidisciplinary Approach: Stroke care requires a team including neurologists, neurosurgeons, radiologists, nurses, physical/occupational/speech therapists, social workers, and case managers.
  • Secondary Prevention is Lifelong: Education and adherence to medication and lifestyle changes are critical to prevent recurrence.
• Pitfalls:
  • Delay in Presentation: Patients and families often delay seeking care. Public education on FAST is vital.
  • Missing LVO: Not all stroke centers have immediate access to CTA. Transfers for EVT can be delayed if LVO is not identified early.
  • Aggressive BP Lowering in Acute Ischemic Stroke (non-tPA): Can extend infarct size.
  • Ignoring Subtle Deficits: Particularly in posterior circulation strokes or non-dominant hemisphere strokes.
  • Underestimating Post-Stroke Depression: Screen and treat aggressively.
  • Premature Discontinuation of Secondary Prevention: Emphasize lifelong adherence to antiplatelets/anticoagulants, statins, and BP meds.

Recent Updates

• Guidelines:
  • 2019 AHA/ASA Guidelines for Early Management of Patients with Acute Ischemic Stroke: Reinforced existing recommendations and expanded the role of EVT for LVO up to 24 hours based on advanced imaging (DAWN, DEFUSE 3 trials). Emphasized time to treatment.
  • 2021 AHA/ASA Guidelines for the Prevention of Stroke in Patients with Stroke and TIA: Updated recommendations for secondary prevention, including DAPT duration, LDL targets, and PFO closure.
  • 2022 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: Updated BP targets and surgical considerations.
• Evidence:
  • Extended Window for EVT: DAWN and DEFUSE 3 trials demonstrated benefit of EVT for select LVO patients up to 16-24 hours from LKN based on perfusion imaging (identifying favorable penumbra).
  • Tenecteplase (TNK) vs. Alteplase (tPA): Emerging evidence suggests TNK may be non-inferior or superior to alteplase for IV thrombolysis, particularly given its ease of administration (single bolus). Ongoing trials continue to refine its role.
  • PFO Closure: Recent meta-analyses and individual trials (CLOSE, RESPECT, REDUCE) have provided stronger evidence for the benefit of PFO closure in selected patients with cryptogenic stroke, especially younger patients, compared to antiplatelet therapy alone.
  • Blood Pressure Targets for ICH: Studies like INTERACT2 and ATACH-2 have informed BP management strategies for ICH, generally favoring rapid, moderate lowering to around 140-160 mmHg.
• Controversies:
  • Optimal LDL-C Target Post-Stroke: While <70 mg/dL is standard, some argue for even lower targets (<55 mg/dL) for very high-risk patients, aligning with CAD guidelines.
  • Optimal Timing for Anticoagulation Post-Cardioembolic Stroke: The exact timing of restarting/initiating anticoagulation after an acute ischemic stroke (due to AFib) remains a balance between preventing recurrent embolism and hemorrhagic transformation, often individualized based on stroke size and risk factors.
  • Role of Routine PFO Screening: While PFO closure is beneficial in select cases, routine screening in cryptogenic stroke patients, and optimal selection criteria, continue to be refined.
  • Prehospital Stroke Scales (e.g., LAMS, RACE): Their optimal use and impact on patient outcomes in different EMS systems are still areas of ongoing study.

Key References

• Guidelines:
  • Powers WJ, Rabinstein AA, Teitelbaum TB, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.
  • Kleindorfer DO, Towfighi ASC, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467.
  • Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361.
• Studies:
  • Nogueira RG, Jadhav AP, Haussen DF, et al. Thrombectomy for Large Ischemic Stroke with Unknown Time of Onset. N Engl J Med. 2018;378(1):11-21 (DAWN Trial).
  • Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Ischemic Stroke with Selection by Perfusion Imaging. N Engl J Med. 2018;378(8):708-718 (DEFUSE 3 Trial).
  • Wahlgren N, Moreira T, Michel P, et al. Mechanical thrombectomy for acute ischemic stroke: a meta-analysis of individual patient data. Lancet. 2016;387(10022):91-98.
  • Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236.
  • Mohr JP, Peyman R, Coull AX, et al. Nimodipine treatment in SAH: The European experience. Stroke. 1993;24(11 Suppl):I29-I35.
  • Anderson CS, Heeley E, Huang Y, et al. Rapid Blood-Pressure Lowering in Patients with Acute Intracerebral Hemorrhage. N Engl J Med. 2013;368(25):2355-2365 (INTERACT2 Trial).
  • SPRINT Trial Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-2116.
• Reviews:
  • UpToDate: Multiple comprehensive reviews on stroke management, pathophysiology, diagnosis, and prevention.
  • Harrison's Principles of Internal Medicine: Chapter on Cerebrovascular Diseases.